Plain-English translation of NCT07226206 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hemophilia A research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new gene therapy called for adults with severe hemophilia A, a bleeding disorder where the body cannot make enough blood clotting protein. You would receive a one-time intravenous infusion of this treatment and then be monitored closely to see if it is safe and how well it works. The study is looking at whether this medication could help reduce bleeding episodes and improve quality of life.
Hemophilia A currently requires regular infusions of clotting factor, which can be burdensome and doesn't completely prevent all bleeds. This trial exists to test whether this new gene therapy approach could offer a longer-lasting or even one-time solution to help the body produce its own clotting factor.
You likely qualify if…
You likely don't qualify if…
You will come to the research clinic on Day 1 to receive a single intravenous infusion of the medication. After that, you will have regular follow-up visits and blood tests over several months to monitor your safety and how well the treatment is working. The study will track your bleeding episodes, your clotting factor levels, and any side effects to understand whether this new therapy is safe and effective for you.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
United States